In the last reported quarter, the company delivered a negative earnings surprise of 22.37%, as seen in the chart below ... competition to Mounjaro/Zepbound and NVO’s Ozempic/Wegovy in the ...

Eli Lilly and Company LLY will report its fourth-quarter and full-year 2024 earnings on Feb. 6, before market open. The Zacks ...

Wall Street investors, spurred on by Trump's pro-business agenda, could be ignoring real risks posed by the president.

The condition appears to be triggered when the optic nerve swells, choking off its blood supply because the nerve's pathway ...

Roche Holding AG delivered a strong set of 2024 earnings. Guidance for 2025 suggests this will be a transitional year ahead, ...

The report projects a 3.84% increase in pharmacy and an increase of 2.3% in non-pharmacy spend over that timeframe. The report also includes a comprehensive analysis of emerging trends and pricing ...

Consensus forecasts for Ozempic, Wegovy, Mounjaro and Zepbound are on track to generate over $70bn in combined sales – and they top the charts of the fastest-growing drugs for the year. The challenge ...

Reports link GLP-1 medications like Ozempic and Mounjaro to vision loss, prompting concerns over their safety.